Mostly Markets
Subscribe
Stocks/Health Care/Life Sciences Tools & Services

Charles River LaboratoriesCRL

Life Sciences Tools & Services · Wilmington, Massachusetts · In the S&P 500
Pricier than peers
$359.41−4.44%After hours: $365.29 (+1.64%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 99.5% over 1 year
Charles River Laboratories over 1 yearDaily close, $, to 30 Oct 2026
$200$300Nov2026MarMayJulSep$359.41$200$300NovMarJul$359.41
Source: Nasdaq daily closes
Market value$17.16B
Price to earnings–
Forward P/E29.1x
Dividend yield–
Year to date+80.2%
One year+99.5%
Next earningsWed 4 Nov, before the open
SectorHealth Care
52-week range (closes)
$149.93$376.10

Quality and valuation

How Charles River Laboratories compares with other health care stocks. A description, not a recommendation.

Charles River Laboratories and 7 life sciences tools & services peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: weaker than mostValuation: pricier than most

A weaker business than most health care companies, priced above most of them.

Charles River Laboratories trades at 29.1 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: −0.7% vs +7.8%
  • Less profitable (operating margin): 2.3% vs 13.3%
  • Turns less of its sales into cash: 9.3% vs 15.9%
CRL trades at 29.1x forward earnings, above the sector medianForward p/e, Life Sciences Tools & Services peers
IQV19.8xDHR26.5xTMO26.6xA26.6xCRL29.1xWAT29.8xMTD34.1xILMN41.6xSector median 19.1xIQV19.8xDHR26.5xTMO26.6xA26.6xCRL29.1xWAT29.8xMTD34.1xILMN41.6xSector median 19.1x
Source: CNBC quotes; Mostly Markets

Financials

From Charles River Laboratories's SEC filings, through the quarter ending 27 Jun 2026. Hover or tap a bar for its value.

Revenue fell 2.7% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0.0bn$0.5bn$1.0bnQ3 ’24Q1 ’25Q3 ’25$1.0bnQ2 ’26$0.0bn$0.5bn$1.0bnQ3 ’24Q1 ’25Q3 ’25$1.0bnQ2 ’26
Source: SEC filings
Growth slowed to −2.7% last quarterRevenue growth, year on year, %
−2%−1%0%1%Q3 ’24Q1 ’25Q3 ’25−2.7%Q2 ’26−2%0%Q3 ’24Q1 ’25Q3 ’25−2.7%Q2 ’26
Source: SEC filings
Operating margin was 11.9% last quarterOperating income as a share of revenue, %
−20%0%Q3 ’24Q1 ’25Q3 ’2511.9%Q2 ’26−20%0%Q3 ’24Q1 ’25Q3 ’2511.9%Q2 ’26
Source: SEC filings
Free cash flow was $371 million over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$100m$200mQ3 ’24Q1 ’25Q3 ’25$149mQ2 ’26$0m$100m$200mQ3 ’24Q1 ’25Q3 ’25$149mQ2 ’26
Source: SEC filings
Last 12 monthsCRLSector median
Revenue growth−0.7%+7.8%
Operating margin2.3%13.3%
Free cash flow margin9.3%15.9%

Stories on Charles River Laboratories

We haven't written about Charles River Laboratories yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Life Sciences Tools & Services, by market value.

CompanyPriceTodayYTDValue
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B
DHRDanaher$232.23−2.00%+1.4%$163B
AAgilent Technologies$174.87−3.47%+28.5%$49.30B
WATWaters$462.72−3.61%+21.8%$45.46B
IQVIQVIA$267.33−2.81%+18.6%$44.06B
ILMNIllumina$235.99−18.64%+79.9%$35.63B
MTDMettler Toledo$1,674.81−2.55%+20.1%$33.56B
TECHBio-Techne$72.66−0.07%+23.6%$11.41B